[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.204.108.121. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
November 1959

Porphyria Cutanea TardaReport of a Case Effectively Treated With Dimercaprol (BAL)

Author Affiliations

Los Angeles

From the Department of Medicine and the Department of Biochemistry and Nutrition, University of Southern California School of Medicine, and the Los Angeles County General Hospital. Instructor in Medicine (Dr. Redeker), Assistant Professor of Biochemistry and Nutrition (Dr. Sterling).

AMA Arch Intern Med. 1959;104(5):779-782. doi:10.1001/archinte.1959.00270110099012
Abstract

Porphyria cutanea tarda (PCT) is one of the inborn porphyrinopathies. It is characterized by abnormal porphyrin synthesis and excretion, cutaneous photodynamic activity, fragility of the skin, and, usually, evidence of liver disease. Schmid, Schwartz, and Watson 1 termed porphyria cutanea tarda and acute intermittent porphyria as hepatic porphyrias, a group of disorders very distinct from congenital (erythropoietic) porphyria. Waldenström2 recognized two forms of porphyria cutanea tarda. One form is familial (PCT hereditaria) and becomes clinically manifest shortly after puberty. It may occasionally be complicated by features of acute porphyria, including the excretion of porphobilinogen in the urine. The other form (PCT symptomatica) becomes manifest later in life and is associated with alcoholism or alcoholic cirrhosis and, in rare instances, with tumors of the liver.

The treatment of porphyria cutanea tarda has been generally disappointing. However, some reports of treatment with dimercaprol (BAL) or edathamil (ethylenediaminetetraacetic acid)3-5 have been

First Page Preview View Large
First page PDF preview
First page PDF preview
×